Drug Profile
Research programme: tubulin targeting agents - Veru Healthcare
Alternative Names: APP-111 analoguesLatest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Ohio State University
- Developer Veru Healthcare
- Class Antineoplastics; Small molecules
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Prostate cancer in USA (PO)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Prostate-cancer in USA (PO)
- 30 Sep 2015 Aspen Park Pharmaceuticals acquires the worldwide rights from the Ohio State University, to develop APP 111 and its analogues